ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Moxifloxacin

Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.

Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.

Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 26, 200755 company-led studies, 2 open or runningNext primary completion: Oct 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only200 open or runningphase 4since Jun 26, 2007Nov 21, 2006none ahead
Alconits history only140 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Pfizerits history only40 open or runningphase 1since Jul 10, 2007Jul 10, 2007none ahead
GlaxoSmithKlineits history only30 open or runningphase 1since Oct 8, 2009Oct 8, 2009none ahead
Da Volterraits history only20 open or runningphase 1since Jun 25, 2014Jun 25, 2014none ahead
Laboratorios Sophia S.A de C.V.its history only21 open or runningphase 3since Jul 30, 2025Apr 9, 2024none ahead
Richmond Pharmacologyits history only20 open or runningphase 1since Jun 19, 2012Jun 19, 2012none ahead
Viatrisits history only20 open or runningphase 1since Sep 7, 2005Sep 7, 2005none ahead
Adapt Produtos Oftalmológicos Ltda.its history only10 open or runningphase 3since Mar 22, 2011Mar 22, 2011none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since Dec 18, 2014Dec 18, 2014none ahead

Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Sep 7, 2005.

  1. May 22, 2013Phase 1 study in HealthyPfizer · NCT01862887 · 48 enrolled · United States
  2. Nov 8, 2013Richmond Research Institute’s first study: phase 1 study in Diabetes MellitusNew to Richmond Research InstituteRichmond Research Institute · NCT01984827 · 24 enrolled · United Kingdom
  3. Jun 25, 2014Da Volterra’s first study: phase 1 study in HealthyNew to Da VolterraDa Volterra · NCT02176005 · 44 enrolled · France
  4. Dec 18, 2014Dr. Reddy's Laboratories’ first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02322619 · 26 enrolled
  5. Jan 1, 2016Intarcia Therapeutics’ first study: phase 1 study in Healthy Adult Male and Female VolunteersNew to Intarcia TherapeuticsIntarcia Therapeutics · NCT02650479 · 82 enrolled · Netherlands
  6. Sep 19, 2016Phase 1 study in Healthy SubjectsDa Volterra · NCT02917200 · 150 enrolled · France
  7. May 18, 2017Phase 1 study in Healthy VolunteersPfizer · NCT03162900 · 36 enrolled · Belgium
  8. Aug 4, 2017Jason Ahee, M.D.’s first study: phase 3 study in EndophthalmitisNew to Jason Ahee, M.D.Jason Ahee, M.D. · NCT03244072 · 60,000 planned · United States
  9. Dec 18, 2019Research Insight’s first study: phase 4 study in CataractNew to Research InsightResearch Insight · NCT04273282 · 31 enrolled · United States
  10. Jan 29, 2020Phase 1 study in Healthy SubjectsViatris · NCT04255277 · 97 enrolled · France
  11. Jul 28, 2022Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT05481528 · 51 enrolled · Germany
  12. Apr 18, 2023No phase study in Diabetes Mellitus, Type 2Richmond Pharmacology · NCT07014735 · 14 enrolled · United Kingdom
  13. Apr 9, 2024Laboratorios Sophia S.A de C.V.’s first study: phase 1 study in Conjunctivitis, BacterialNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT06363292 · 37 enrolled · Mexico
  14. Jul 30, 2025Phase 3 study in Cataract ExtractionLaboratorios Sophia S.A de C.V. · NCT07305987 · 134 planned · Mexico

Ahead

  1. Oct 2030Primary completion: phase 3 study in EndophthalmitisJason Ahee, M.D. · NCT03244072

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule

Studies

All 55 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07305987Cataract Extraction · Mexico3RecruitingLaboratorios Sophia S.A de C.V.Jun 30, 2026134
NCT06363292Conjunctivitis, Bacterial · Mexico1CompletedLaboratorios Sophia S.A de C.V.May 28, 202437
NCT07014735Diabetes Mellitus, Type 2 · United Kingdom–TerminatedRichmond PharmacologyMay 31, 202614
NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerFeb 7, 202351
NCT04255277Healthy Subjects · France1CompletedViatrisSep 14, 202197
NCT04273282Cataract · United States4CompletedResearch InsightNov 24, 202031
NCT03244072Endophthalmitis · United States3Not yet recruitingJason Ahee, M.D.Oct 203060,000
NCT03162900Healthy Volunteers · Belgium1CompletedPfizerSep 23, 201736
NCT02917200Healthy Subjects · France1CompletedDa VolterraDec 2, 2016150
NCT02650479Healthy Adult Male and Female Volunteers · Netherlands1CompletedIntarcia TherapeuticsApr 201682
NCT02322619Healthy1CompletedDr. Reddy's LaboratoriesDec 201226
NCT02176005Healthy · France1CompletedDa VolterraOct 201444
NCT01984827Diabetes Mellitus · United Kingdom1CompletedRichmond Research InstituteDec 31, 202024
NCT01862887Healthy · United States1CompletedPfizerAug 201348
NCT01859702Cataract4CompletedAlconAug 201236
NCT01775761TTR Cardiomyopathy · United States, Belgium, Singapore1CompletedPfizerApr 201342
NCT01642485Insulin Resistance · United Kingdom1CompletedRichmond PharmacologySep 201132
NCT01573910Conjunctivitis, Bacterial · China3CompletedAlconApr 2014985
NCT01515826Cataract3WithdrawnAlconOct 20140
NCT01449188Nausea · United States1CompletedGlaxoSmithKlineDec 19, 201160
NCT01406262Diabetes Mellitus, Type 21CompletedGlaxoSmithKlineDec 29, 201194
NCT01603030Eye Infections · Brazil3UNKNOWNAdapt Produtos Oftalmológicos Ltda.Aug 201266
NCT01238783Conjunctivitis, Bacterial2WithdrawnAlconDec 20110
NCT01073891Healthy · Germany1CompletedBayerNov 201024
NCT01071902Otitis Media · United States3TerminatedAlconOct 2011400
NCT01069900Intraabdominal Infections · United States, Argentina, Bulgaria and more3CompletedBayerJan 21, 2015458
NCT01049022Infections · United States1CompletedBayerDec 201231
NCT01045902Pneumonia, Aspiration · Germany3CompletedBayer139
NCT01014247QTc Evaluation · Australia, Germany, Singapore and more1CompletedBayerJun 201056
NCT00996021Healthy Subjects · United States1CompletedGlaxoSmithKlineNov 200942
NCT00840580Cataract · Korea, Republic of4CompletedAlconSep 200979
NCT00828971Communicable Diseases · Italy3CompletedBayerSep 200916
NCT00798577Conjunctivitis, Bacterial · United States4CompletedAlconFeb 200924
NCT00769171Intraabdominal Infections · China, Hong Kong, Indonesia and more3CompletedBayerDec 2006364
NCT00870103Cataract · United States4CompletedAlconFeb 200964
NCT00750633Otitis Externa3CompletedAlconJan 2009990
NCT00717561Pneumonia · Italy3CompletedBayerMay 200960
NCT00683865Pelvic Inflammatory Disease · Denmark, Finland, France and more3CompletedBayerOct 2004749
NCT00668304Maxillary Sinusitis · United States, Argentina4CompletedBayer192
NCT00665327Pneumonia · United States, Puerto Rico4CompletedBayerApr 2004401
NCT00656747Bronchitis, Chronic · Andorra, Argentina, Australia and more4CompletedBayerDec 20101,372
NCT00579189Otitis Media3CompletedAlconJan 2009776
NCT00579020Corneal Diseases · United States2TerminatedAlconFeb 2009144
NCT00578773Otitis Media2CompletedAlconJan 2009303
NCT00578474Otitis Media3CompletedAlconAug 2008911
NCT00499642Alzheimer Disease · France1CompletedPfizer
NCT00493038Sinusitis · Italy4TerminatedBayerJan 2008293
NCT00492726Infections · Argentina, Belgium, Bulgaria and more3CompletedBayerFeb 2009804
NCT00492024Sinusitis · United States3CompletedBayerMar 2008374
NCT00473460Lung Diseases · United States, Andorra, Argentina and more3CompletedBayerJan 20071,404
NCT00453349Pelvic Inflammatory Disease · China, Indonesia, Korea, Republic of and more3CompletedBayerMay 2008460
NCT00431678Pneumonia · Argentina, Belgium, Chile and more3CompletedBayerJul 2005738
NCT00402727Abscess · Austria, Belgium, Bulgaria and more3CompletedBayerJun 2008813
NCT00312338Conjunctivitis, Bacterial · United States4CompletedAlconJun 2007137
NCT00158093Hypertension · United States1CompletedViatris260

How it is read

Names in the registry

  • “Moxifloxacin”, 32 entries
  • “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
  • “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
  • “moxifloxacin”, 6 entries
  • “Moxidex otic solution”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.